Giselle Y. López
YOU?
Author Swipe
View article: IMG-121. BraTS-Pathology 2024: Insights and Future Directions Informed by the AI-RANO & RANO-RGP Effort to Assess Glioblastoma Heterogeneity
IMG-121. BraTS-Pathology 2024: Insights and Future Directions Informed by the AI-RANO & RANO-RGP Effort to Assess Glioblastoma Heterogeneity Open
INTRODUCTION Glioblastoma is the most common malignant adult brain tumor with poor prognosis, largely due to its heterogeneous landscape. The AI-RANO and RANO-RGP groups organized the BraTS-Pathology 2024 challenge, providing a publicly-av…
View article: EXTH-138. GD2 as an Immunotherapeutic Target in Oligodendroglioma: Preclinical Evidence Supporting CAR T Cell Therapy
EXTH-138. GD2 as an Immunotherapeutic Target in Oligodendroglioma: Preclinical Evidence Supporting CAR T Cell Therapy Open
BACKGROUND Oligodendrogliomas are a distinct subtype of diffuse gliomas that arise from glial cells resembling oligodendrocytes. While associated with a relatively favorable prognosis compared to other diffuse gliomas, oligodendrogliomas a…
View article: BIOM-72. INTEGRATIVE SINGLE-NUCLEI SPATIAL TRANSCRIPTOMIC PROFILING OF PRIMARY AND RECURRENT HUMAN IDH-WILDTYPE GLIOBLASTOMA REVEALS CELL-SPECIFIC EGFRVIII EXPRESSION AND ANXA1 SIGNALING AXIS
BIOM-72. INTEGRATIVE SINGLE-NUCLEI SPATIAL TRANSCRIPTOMIC PROFILING OF PRIMARY AND RECURRENT HUMAN IDH-WILDTYPE GLIOBLASTOMA REVEALS CELL-SPECIFIC EGFRVIII EXPRESSION AND ANXA1 SIGNALING AXIS Open
The World Health Organization provides clear criteria for diagnosing IDH1-wildtype glioblastoma (GBM), relying on traditional approaches to define pathoetiological features, genomic mutations, copy number variation, and aberrant expression…
View article: A surgical window of opportunity trial evaluating the effect of the PCSK9 inhibitor evolocumab on tumoral MHC-I expression and CD8+ infiltration in glioma
A surgical window of opportunity trial evaluating the effect of the PCSK9 inhibitor evolocumab on tumoral MHC-I expression and CD8+ infiltration in glioma Open
View article: EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis
EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis Open
View article: A surgical window of opportunity trial evaluating the effect of the PCSK9 inhibitor evolocumab on tumoral MHC-I expression and CD8+ infiltration in glioma
A surgical window of opportunity trial evaluating the effect of the PCSK9 inhibitor evolocumab on tumoral MHC-I expression and CD8+ infiltration in glioma Open
Many cancers evade immunosurveillance by downregulating surface major histocompatibility class (MHC)-I. Proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes MHC-I degradation and is elevated in glioma. Evolocumab is a clinically …
View article: Publisher Correction: Ganglioglioma deep transcriptomics reveals primitive neuroectoderm neural precursor‑like population
Publisher Correction: Ganglioglioma deep transcriptomics reveals primitive neuroectoderm neural precursor‑like population Open
View article: A surgical window of opportunity trial evaluating the effect of the PCSK9 inhibitor evolocumab on tumoral MHC-I expression and CD8<sup>+</sup> infiltration in glioma
A surgical window of opportunity trial evaluating the effect of the PCSK9 inhibitor evolocumab on tumoral MHC-I expression and CD8<sup>+</sup> infiltration in glioma Open
Many cancers evade immunosurveillance by downregulating surface major histocompatibility class (MHC)-I. Proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes MHC-I degradation and is elevated in glioma. Evolocumab is a clinically …
View article: BraTS-Path Challenge: Assessing Heterogeneous Histopathologic Brain Tumor Sub-regions
BraTS-Path Challenge: Assessing Heterogeneous Histopathologic Brain Tumor Sub-regions Open
Glioblastoma is the most common primary adult brain tumor, with a grim prognosis - median survival of 12-18 months following treatment, and 4 months otherwise. Glioblastoma is widely infiltrative in the cerebral hemispheres and well-define…
View article: PATH-23. CLINICOPATHOLOGIC ANALYSIS OF NOVEL METHYLATION CLUSTERS OF IDH-WILDTYPE DIFFUSE GLIOMAS
PATH-23. CLINICOPATHOLOGIC ANALYSIS OF NOVEL METHYLATION CLUSTERS OF IDH-WILDTYPE DIFFUSE GLIOMAS Open
Methylation profiling of brain tumors has revealed novel clusters whose biological and clinical significance is unknown. These include three entities termed by the 12.5 version of the Heidelberg methylation classifier as adult-type diffuse…
View article: CSIG-07. HYPERCELLULAR NODULES IN OLIGODENDROGLIOMA REPRESENT POCKETS OF PROLIFERATIVE STEM-LIKE TUMOR CELLS
CSIG-07. HYPERCELLULAR NODULES IN OLIGODENDROGLIOMA REPRESENT POCKETS OF PROLIFERATIVE STEM-LIKE TUMOR CELLS Open
INTRODUCTION Oligodendrogliomas are a progressive, infiltrative glioma. By histology, a subset of oligodendrogliomas demonstrate hypercellular nodules (HCN), which often have increased anaplasia compared to surrounding tumor. However, the …
View article: LGG-13. GANGLIOGLIOMA DEEP TRANSCRIPTOMICS REVEALS A CD34+ PRIMITIVE NEUROECTODERM NEURAL PRECURSOR-LIKE POPULATION
LGG-13. GANGLIOGLIOMA DEEP TRANSCRIPTOMICS REVEALS A CD34+ PRIMITIVE NEUROECTODERM NEURAL PRECURSOR-LIKE POPULATION Open
Gangliogliomas are glioneuronal brain tumors that typically present in childhood or early adulthood. Though most often low-grade, new insights are needed to refine glioneuronal tumor classification and to identify therapeutic approaches, p…
View article: Data from Disruption of Wild-Type IDH1 Suppresses D-2-Hydroxyglutarate Production in IDH1-Mutated Gliomas
Data from Disruption of Wild-Type IDH1 Suppresses D-2-Hydroxyglutarate Production in IDH1-Mutated Gliomas Open
Point mutations at Arg132 of the cytoplasmic NADP+-dependent isocitrate dehydrogenase 1 (IDH1) occur frequently in gliomas and result in a gain of function to produce the “oncometabolite” D-2-hydroxyglutarate (D-2HG). The mutate…
View article: Supplementary Figure 3 from Disruption of Wild-Type IDH1 Suppresses D-2-Hydroxyglutarate Production in IDH1-Mutated Gliomas
Supplementary Figure 3 from Disruption of Wild-Type IDH1 Suppresses D-2-Hydroxyglutarate Production in IDH1-Mutated Gliomas Open
PDF file-101KB, Mutant IDH1 in the absence of wild type IDH1 is not sufficient to efficiently produce D-2HG in HCT116 cells
View article: Supplementary Figure 3 from Disruption of Wild-Type IDH1 Suppresses D-2-Hydroxyglutarate Production in IDH1-Mutated Gliomas
Supplementary Figure 3 from Disruption of Wild-Type IDH1 Suppresses D-2-Hydroxyglutarate Production in IDH1-Mutated Gliomas Open
PDF file-101KB, Mutant IDH1 in the absence of wild type IDH1 is not sufficient to efficiently produce D-2HG in HCT116 cells
View article: Supplementary Table 1 from Disruption of Wild-Type IDH1 Suppresses D-2-Hydroxyglutarate Production in IDH1-Mutated Gliomas
Supplementary Table 1 from Disruption of Wild-Type IDH1 Suppresses D-2-Hydroxyglutarate Production in IDH1-Mutated Gliomas Open
PDF file-22KB, D-2HG in primary human glioma tissue samples, as assessed by LC-MS/MS
View article: Supplementary Figure 2 from Disruption of Wild-Type IDH1 Suppresses D-2-Hydroxyglutarate Production in IDH1-Mutated Gliomas
Supplementary Figure 2 from Disruption of Wild-Type IDH1 Suppresses D-2-Hydroxyglutarate Production in IDH1-Mutated Gliomas Open
PDF file-28KB, Comparison of growth and apoptosis for parental IMA cells and IMA cells with the IDH1-WT allele knocked out (KO)
View article: Supplementary Figure 1 from Disruption of Wild-Type IDH1 Suppresses D-2-Hydroxyglutarate Production in IDH1-Mutated Gliomas
Supplementary Figure 1 from Disruption of Wild-Type IDH1 Suppresses D-2-Hydroxyglutarate Production in IDH1-Mutated Gliomas Open
PDF file-31KB, Synthesis of octyl-�-ketoglutarate
View article: Data from Disruption of Wild-Type IDH1 Suppresses D-2-Hydroxyglutarate Production in IDH1-Mutated Gliomas
Data from Disruption of Wild-Type IDH1 Suppresses D-2-Hydroxyglutarate Production in IDH1-Mutated Gliomas Open
Point mutations at Arg132 of the cytoplasmic NADP+-dependent isocitrate dehydrogenase 1 (IDH1) occur frequently in gliomas and result in a gain of function to produce the “oncometabolite” D-2-hydroxyglutarate (D-2HG). The mutate…
View article: Supplementary Table 2 from Disruption of Wild-Type IDH1 Suppresses D-2-Hydroxyglutarate Production in IDH1-Mutated Gliomas
Supplementary Table 2 from Disruption of Wild-Type IDH1 Suppresses D-2-Hydroxyglutarate Production in IDH1-Mutated Gliomas Open
PDF file-23KB, D-2HG in cell line lysate samples, as assessed by LC-MS/M
View article: Supplementary Table 2 from Disruption of Wild-Type IDH1 Suppresses D-2-Hydroxyglutarate Production in IDH1-Mutated Gliomas
Supplementary Table 2 from Disruption of Wild-Type IDH1 Suppresses D-2-Hydroxyglutarate Production in IDH1-Mutated Gliomas Open
PDF file-23KB, D-2HG in cell line lysate samples, as assessed by LC-MS/M
View article: Supplementary Table 1 from Disruption of Wild-Type IDH1 Suppresses D-2-Hydroxyglutarate Production in IDH1-Mutated Gliomas
Supplementary Table 1 from Disruption of Wild-Type IDH1 Suppresses D-2-Hydroxyglutarate Production in IDH1-Mutated Gliomas Open
PDF file-22KB, D-2HG in primary human glioma tissue samples, as assessed by LC-MS/MS
View article: Supplementary Figure 2 from Disruption of Wild-Type IDH1 Suppresses D-2-Hydroxyglutarate Production in IDH1-Mutated Gliomas
Supplementary Figure 2 from Disruption of Wild-Type IDH1 Suppresses D-2-Hydroxyglutarate Production in IDH1-Mutated Gliomas Open
PDF file-28KB, Comparison of growth and apoptosis for parental IMA cells and IMA cells with the IDH1-WT allele knocked out (KO)
View article: Supplementary Figure 1 from Disruption of Wild-Type IDH1 Suppresses D-2-Hydroxyglutarate Production in IDH1-Mutated Gliomas
Supplementary Figure 1 from Disruption of Wild-Type IDH1 Suppresses D-2-Hydroxyglutarate Production in IDH1-Mutated Gliomas Open
PDF file-31KB, Synthesis of octyl-�-ketoglutarate
View article: Ganglioglioma deep transcriptomics reveals primitive neuroectoderm neural precursor-like population
Ganglioglioma deep transcriptomics reveals primitive neuroectoderm neural precursor-like population Open
View article: Ganglioglioma deep transcriptomics reveals primitive neuroectoderm neural precursor-like population
Ganglioglioma deep transcriptomics reveals primitive neuroectoderm neural precursor-like population Open
Gangliogliomas are brain tumors composed of neuron-like and macroglia-like components that occur in children and young adults. Gangliogliomas are often characterized by a rare population of immature astrocyte-appearing cells expressing CD3…
View article: Ganglioglioma deep transcriptomics reveals primitive neuroectoderm neural precursor-like population
Ganglioglioma deep transcriptomics reveals primitive neuroectoderm neural precursor-like population Open
Ganglioglioma tumor single nucleus RNA sequencing, cellular indexing of transcriptomes by sequencing, and spatial transcriptomics data sets to accompany manuscript of the same title posted to BioRxiv.
View article: Ganglioglioma deep transcriptomics reveals primitive neuroectoderm neural precursor-like population
Ganglioglioma deep transcriptomics reveals primitive neuroectoderm neural precursor-like population Open
Ganglioglioma tumor single nucleus RNA sequencing, cellular indexing of transcriptomes by sequencing, and spatial transcriptomics data sets to accompany manuscript of the same title posted to BioRxiv.
View article: Ganglioglioma deep transcriptomics reveals primitive neuroectoderm neural precursor-like population
Ganglioglioma deep transcriptomics reveals primitive neuroectoderm neural precursor-like population Open
Ganglioglioma tumor single nucleus RNA sequencing, cellular indexing of transcriptomes by sequencing, and spatial transcriptomics data sets to accompany manuscript of the same title posted to BioRxiv.
View article: PATH-22. CLINICAL FEATURES AND MOLECULAR CHARACTERIZATION OF LEPTOMENINGEAL DISEASE IN PATIENTS WITH HIGH GRADE GLIOMA
PATH-22. CLINICAL FEATURES AND MOLECULAR CHARACTERIZATION OF LEPTOMENINGEAL DISEASE IN PATIENTS WITH HIGH GRADE GLIOMA Open
INTRODUCTION Leptomeningeal disease (LMD) is a challenging complication of high grade glioma (HGG) and critical questions remain unanswered regarding clinicopathologic risk factors, molecular associations, and optimal treatment. METHODS Pa…